id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-012117-c693oefo	Diaz-Padilla, Ivan	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors	2013-10-01		.txt	text/plain	4691	273	49	Dose-limiting toxicities (DLTs) were defined as adverse events (AEs) as least possibly related to study medication(s) and fulfilling one of the following criteria: a) grade 3 or 4 neutropenia complicated by fever ≥38.5°C, or grade 4 neutropenia of at least 7 days duration; b) grade 3 thrombocytopenia complicated by hemorrhage or grade 4 thrombocytopenia; or c) any grade 3 or higher non-hematologic toxicity (except anorexia, nausea, vomiting, and diarrhea that was not optimally controlled with appropriate medical intervention); d) any ≥grade 3 electrolyte abnormality including hypophosphatemia, hypocalcemia, or hypomagnesemia that did not resolve within 72 h with appropriate therapy or if it was associated with new ECG changes; e) treatment-related toxicities that resulted in failure to receive at least 75 % of the planned doses of RO4929097 and of temsirolimus despite maximal supportive care measures; f) inability to resume dosing for cycle 2 at the current dose level within 14 days due to treatment-related toxicity.	./cache/cord-012117-c693oefo.txt	./txt/cord-012117-c693oefo.txt